Dose-response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man

Anesthesiology

Volumn 125, Issue 6, 2016, Pages 1136-1143

  Heerdt, Paul M ^a   Sunaga, Hiroshi ^b   Owen, Joel S ^c   Murrell, Matthew T ^b   Malhotra, Jaideep K ^b   Godfrey, Deena ^b   Steinkamp, Michelle ^b   Savard, Peter ^b   Savarese, John J ^b   Lien, Cynthia A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CW 002; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; SEVOFLURANE; UNCLASSIFIED DRUG; ISOQUINOLINE DERIVATIVE;

ADULT; ARTERIAL BLOOD; ARTICLE; BLOOD PRESSURE; CARDIOPULMONARY FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FEMALE; FIRST IN HUMAN STUDY; HEART RATE; HISTAMINE BLOOD LEVEL; HISTAMINE RELEASE; HUMAN; MALE; NEUROMUSCULAR BLOCKING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ADOLESCENT; BREATHING; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HISTAMINE RELEASE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; RESPIRATION; YOUNG ADULT;

EID: 84991489693     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001386     Document Type: Article

References (28)

1. Heerdt PM, Malhotra JK, Pan BY, Sunaga H, Savarese JJ: Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. Anesthesiology 2010; 112:910-6
2. Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM: Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: Pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology 2010; 112:900-9
3. Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ: Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care 2009; 24:50-7
4. Boros EE, Bigham EC, Boswell GE, Mook RA Jr, Patel SS, Savarese JJ, Ray JA, Thompson JB, Hashim MA, Wisowaty JC, Feldman PL, Samano V: Bis-and mixed-tetrahydroisoquinolinium chlorofumarates: New ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem 1999; 42:206-9
5. Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM: Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology 2010; 113:58-73
6. Diaz LL, Zhang J, Heerdt PM: Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits. J Am Assoc Lab Anim Sci 2014; 53:283-9
7. Sunaga H, Savarese JJ, McGilvra JD, Heerdt PM, Belmont MR, Van Ornum SG, Murrell MT, Malhotra JK, Savard PM, Jeannotte E, Allen E, Carnathan GW. Preclinical pharmacology of CW002: A nondepolarizing neuromuscular blocking drug of intermediate duration, degraded and antagonized by L-cysteine: Additional Studies of Safety and Efficacy in the Anesthetized Rhesus Monkey and Cat. Anesthesiology 2016; 125:732-43
8. Sunaga H, Zhang Y, Savarese JJ, Emala CW: Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology 2010; 112:892-9
9. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting: Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: The Stockholm revision. Acta Anaesthesiol Scand 2007; 51:789-808
10. Kopman AF, Lien CA, Naguib M: Neuromuscular doseresponse studies: Determining sample size. Br J Anaesth 2011; 106:194-8
11. Pollock I, Murdoch RD, Lessof MH: Plasma histamine and clinical tolerance to infused histamine in normal, atopic and urticarial subjects. Agents Actions 1991; 32:359-65
12. Dyer J, Warren K, Merlin S, Metcalfe DD, Kaliner M: Measurement of plasma histamine: Description of an improved method and normal values. J Allergy Clin Immunol 1982; 70:82-7
13. Kaliner M, Shelhamer JH, Ottesen EA: Effects of infused histamine: Correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol 1982; 69:283-9
14. Kopman AF, Lien CA, Naguib M: Determining the potency of neuromuscular blockers: Are traditional methods flawed? Br J Anaesth 2010; 104:705-10
15. Motulsky HJ, Brown RE: Detecting outliers when fitting data with nonlinear regression-A new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 2006; 7:123
16. Fisher DM, Rosen JI: A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. Anesthesiology 1986; 65:286-91
17. Samano V, Ray JA, Thompson JB, Mook RA Jr, Jung DK, Koble CS, Martin MT, Bigham EC, Regitz CS, Feldman PL, Boros EE: Synthesis of ultra-short-acting neuromuscular blocker GW 0430: A remarkably stereo-and regioselective synthesis of mixed tetrahydroisoquinolinium chlorofumarates. Org Lett 1999; 1:1993-6
18. Kaldor I, Feldman PL, Mook RA Jr, Ray JA, Samano V, Sefler AM, Thompson JB, Travis BR, Boros EE: Stereocontrolled synthesis of cis-dibenzoquinolizine chlorofumarates: Curare-like agents of ultrashort duration. J Org Chem 2001; 66:3495-501
19. Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB: Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: A comparison with mivacurium. Anesthesiology 2004; 100:835-45
20. Heerdt PM, Kang R, The A, Hashim M, Mook RJ Jr, Savarese JJ: Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology 2004; 100:846-51
21. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ: Clinical pharmacology of GW280430A in humans. Anesthesiology 2004; 100:768-73
22. Wulf H, Ledowski T, Linstedt U, Proppe D, Sitzlack D: Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia. Can J Anaesth 1998; 45:526-32
23. Vanlinthout LE, Booij LH, van Egmond J, Robertson EN: Effect of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pancuronium and atracurium. Br J Anaesth 1996; 76:389-95
24. Wulf H, Kahl M, Ledowski T: Augmentation of the neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane or total i. v. Anaesthesia. Br J Anaesth 1998; 80:308-12
25. Bock M, Klippel K, Nitsche B, Bach A, Martin E, Motsch J: Rocuronium potency and recovery characteristics during steady-state desflurane, sevoflurane, isoflurane or propofol anaesthesia. Br J Anaesth 2000; 84:43-7
26. Lowry DW, Mirakhur RK, McCarthy GJ, Carroll MT, McCourt KC: Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia. Anesth Analg 1998; 87:936-40
27. De Wolf AM, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR: Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996; 76:624-8
28. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR: Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83:1065-71